Heart failure in 2004;La insuficiencia cardíaca en el año 2004

Revista Espanola de Cardiologia Suplementos

Volumn 5, Issue A, 2005, Pages

  Crespo Leiro, María G ^a,b   Navarro, Manuel Jiménez ^c   Pulpón, Luis Alonso ^d   Cuenca Castillo, José J ^a,b   Aguilera, Roberto Muñoz ^e   Avilés, Francisco Fernández ^b,f  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

Author keywords

Cell therapy; Heart failure; Heart transplantation; Left ventricular reconstruction; Resynchronization therapy; Ventricular assist devices

Indexed keywords

AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CAPTOPRIL; CYCLOSPORIN A; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; EVEROLIMUS; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; LEVOSIMENDAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; SPIRONOLACTONE; STEROID; TOLVAPTAN; VALGANCICLOVIR; VALSARTAN;

ANGIOCARDIOGRAPHY; CARDIAC RESYNCHRONIZATION THERAPY; CELL THERAPY; CLINICAL PRACTICE; DEFIBRILLATOR; DRUG DOSE COMPARISON; HEART FAILURE; HEART INFARCTION; HEART SURGERY; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; REVIEW;

EID: 35948952010     PISSN: 11313587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1131-3587(05)74099-1     Document Type: Article

References (79)

1. Anguita Sánchez M, Torres Calvo F, Vallés Belsué F. La insuficiencia cardíaca en el año 2003. Rev Esp Cardiol. 2004;4 Supl A:26-35.
2. Cowie M, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R, et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J. 2003;24:1710-8.
3. Wright S, Doughty R, Pearl A, Gamble G, Whalley G, Walsh H, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol. 2003;42:1793-800.
4. Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E, López L, Cotes C, Bellido J, et al. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail. 2004;6:301-8.
5. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647-54.
6. Rivera M, Talens-Visconti R, Salvador A, Bertomeu V, Miro V, García de Burgos F, et al. Hipertensión y valores de NT-proBNP. Su importancia en el diagnóstico de insuficiencia cardíaca. Rev Esp Cardiol. 2004;57:396-402.
7. McCullough P, Hollander J, Nowak R, Storrow A, Duc P, Omland T, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med. 2003;10:275-7.
8. Tang W, Girod J, Lee M, Starling R, Young J, Van Lente F, et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation. 2003;108:2950-3.
9. Packer M. Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? Circulation. 2003;108:2964-6.
10. Cleland J, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar J, et al. The Euro Heart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24:442-63.
11. Senni M, Rodeheffer R, Tribouilloy C, Evans J, Jacobsen S, Bailey K, et al. Use of echocardiography in the management of congestive heart failure in the community. J Am Coll Cardiol. 1999;33:164-70.
12. Martin-Penato A, Zamorano J, Almeria C, Rodrigo J, Corros C, Luaces M, et al. Ecocardiografía portátil: ¿qué añade a la valoración cardiovascular inicial? Rev Esp Cardiol. 2003;56:1069-76.
13. Vourvouri E, Schinkel A, Roelandt J, Boomsma F, Sianos G, Bountioukos M, et al. Screening for left ventricular dysfunction using a hand-carried cardiac ultrasound device. Eur J Heart Failure. 2003;5:767-74.
14. Khunti K. Systematic review of open access echocardiography for primary care. Eur J Heart Fail. 2004;6:79-83.
15. Pfeffer M, McMurray J, Velázquez E, Rouleau J, Kober L, Maggioni A, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-906.
16. Gheorghiade M, Gattis W, O'Connor C, Adams K, Elkayam U, Barbagelata A, et al. Effects of tolvaptan, a vasopresin antagonist, in patients hospitalized with worsening heart failure. A randomized controlled trial. JAMA. 2004;16:1963-71.
17. Anand I, McMurray J, Cohn J, Konstam M, Notter T, Quitzau K, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelina Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:347-54.
18. Cleland J, Ghosh J, Freemantle N, Kaye G, Nasir M, Clark A, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINA-MIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail. 2004;6:501-8.
19. Taylor D, Edwards L, Boucek M, Trulock E, Keck B, Hertz M. The Registry of the International Society for Heart and Lung Transplantation: Twenty-first Official Adult Heart Transplant Report-2004. J Heart Lung Transplant. 2004;23:796-803.
20. Almenar Bonet L. Registro Español de Trasplante Cardíaco. XIV Informe Oficial de la Sección de Insuficiencia Cardíaca, Trasplante Cardíaco y Otras Alternativas Terapéuticas de la Sociedad Española de Cardiología (1984-2002). Rev Esp Cardiol. 2003;56:1210-7.
21. Park M, Uber P, Scott R, Mehra M. B-type natriuretic peptide in heart transplantation: an important marker of allograft performance. Heart Fail Rev. 2003;8:359-63.
22. Arnau-Vives M, Almenar L, Hervas I, Osa A, Martínez-Dolz L, Rueda J, et al. Predictive value of brain natriuretic peptide in the diagnosis of heart transplant rejection. J Heart Lung Transplant. 2004;23:850-6.
23. Mehra M, Uber P, Potluri S, Ventura H, Scott R, Park M. Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation. Am J Cardiol. 2004;94:454-8.
24. Kobashigawa J. First-year intravascular ultrasound results as a surrogate marker for outcomes after heart transplantation. J Heart Lung Transplant. 2003;22:711-4.
25. Mehra M, Ventura H, Uber P, Scott R, Park M. Is all intimal proliferation created equal in cardiac allograft vasculopathy? The quantity-quality paradox. J Heart Lung Transplant. 2003;22:118-23.
26. Eisen H, Tuzcu E, Dorent R, Kobashigawa J, Mancini D, Valantine von Kaeppler H, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplants recipients. N Engl J Med. 2003;349:847-58.
27. Keogh A, Richardson M, Ruygrok P, Spratt P, Galbraith A, O'Driscoll G, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. A randomized clinical trial. Circulation. 2004;110:R10-R6.
28. Paya C, Humar A, Domínguez E, Washburn K, Blumberg E, Alexander B, et al. Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4:611-20.
29. White H, Norris R, Brown M, Brandt P, Whitlock R, Wild C. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76:44-51.
30. Kono T, Sabbah H, Rosman H, Alam M, Jafri S, Goldstein S. Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. J Am Coll Cardiol. 1992;20:1594-8.
31. Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation. 1993;87:755-63.
32. Yamaguchi A, Ino T, Adachi H, Mizuhara A, Murata S, Kamio H. Left ventricular end-systolic volume index in patients with ischemic cardiomyopathy predicts postoperative ventricular function. Ann Thorac Surg. 1995;60:1059-62.
33. Yamaguchi A, Ino T, Adachi H, Murata S, Kamio H, Okada M, et al. Left ventricular volume predicts postoperative course in patients with ischemic cardiomyopathy. Ann Thorac Surg. 1998;65:434-8.
34. Schinkel A, Poldermans D, Rizzello V, Vanoverschelde J, Elhendy A, Boersma E, et al. Why do patients with ischemic cardiomyopathy and a substantial amount of viable myocardium not always recover in function after revascularization? J Thorac Cardiovasc Surg. 2004;127:185-90.
35. Comin J, Manito N, Roca J, Castells E, Esplugas E. Insuficiencia mitral funcional. Fisiopatología e impacto del tratamiento médico y de las técnicas quirúrgicas de reducción ventricular izquierda. Rev Esp Cardiol. 1999;52:512-20.
36. Maxey T, Reece T, Ellman P, Butler P, Kern J, Tribble C, et al. Coronary artery bypass with ventricular restoration is superior to coronary artery bypass alone in patients with ischemic cardiomyopathy. J Thorac Cardiovasc Surg. 2004;127:428-34.
37. Athanasuleas C, Stanley AJ, Buckberg G, Dor V, DiDonato M, Blackstone E. Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. J Am Coll Cardiol. 2001;37:1199-209.
38. Dor V. Surgical remodeling of left ventricle. Surg Clin North Am. 2004;84:27-43.
39. Dor V. Left ventricular reconstruction: the aim and the reality after twenty years. J Thorac Cardiovasc Surg. 2004;128:17-20.
40. Di Donato M, Sabatier M, Toso A. Efficacy of Dor procedure on late survival in patients with post-infarction akinetic or dyskinetic scar and predictors outcome. J Am Coll Cardiol. 2001;30 Suppl A:370.
41. Schenk S, McCarthy P, Starling R, Hoercher K, Hail M, Ootaki Y, et al. Neurohormonal response to left ventricular reconstruction surgery in ischemic cardiomyopathy. J Thorac Cardiovasc Surg. 2004;128:38-43.
42. Mickleborough L, Merchant N, Provost Y, Carson S, Ivanov J. Ventricular reconstruction for ischemic cardiomyopathy. Ann Thorac Surg. 2003;75 Suppl 6:6-12.
43. Mickleborough L, Merchant N, Ivanov J, Rao V, Carson S. Left ventricular reconstruction: early and late results. J Thorac Cardiovasc Surg. 2004;128:27-37.
44. Buckberg G. Early and late results of left ventricular reconstruction in thin-walled chambers: is this our patient population? J Thorac Cardiovasc Surg. 2004;128:21-6.
45. Rose E, Gelinjns A, Moskowitz A. Randomized evaluation of mechanical assistance for the treatment of congestive heart failure (REMATCH) study group. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001;345:1435-43.
46. Lazar R, Shapiro P, Jaski B, Parides M, Bourge R, Watson J, et al. Neurological events during long-term mechanical circulatory support for heart failure: the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) experience. Circulation. 2004;109:2423-7.
47. Frazier O, Delgado R. Mechanical circulatory support for advanced heart failure: where does it stand in 2003? Circulation. 2003;108:3064-8.
48. Stevenson L, Rose E. Left ventricular assist devices. Bridges to transplantation, recovery, and destination for whom? Circulation. 2003;108:3059-63.
49. Oz M, Gelijns A, Miller L, Wang C, Nickens P, Arons R, et al. Left ventricular assist devices as permanent heart failure therapy: the price of progress. Ann Surg. 2004;238:577-83.
50. Frazier O, Myers T, Westaby S, Gregoric I. Clinical experience with an implantable, intracardiac, continuous flow circulatory support device: physiologic implications and their relationship to patient selection. Ann Thorac Surg. 2004;77:133-42.
51. Fernández A, Garca-Bengochea J, Ledo R, Vega M, Amaro A, Álvarez J, et al. Implante de electrodos epicárdicos en el ventrículo izquierdo para resincronización mediante cirugía mínimamente invasiva asistida por videotoracospocia. Rev Esp Cardiol. 2004;57:313-9.
52. Muñoz R, Serrano J, Pascual DG. Resincronización ventricular: una terapéutica emergente. Rev Esp Cardiol. 2004;57:279-82.
53. Auricchio A, Stellbrink C, Butter C, Sack S, Vogt J, Misier A, et al. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. J Am Coll Cardiol. 2003;42:2109-16.
54. Bristow M, Saxon L, Boehmer J, Krueger S, Kass D, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-50.
55. Achilli A, Sassara M, Ficili S, Pontillo D, Achilli P, Alessi C, et al. Long-term effectiveness of cardiac resynchronization therapy in patients with refractory heart failure and «narrow» QRS. J Am Coll Cardiol. 2003;42:2117-24.
56. Yu C, Lin H, Zhang Q, Sanderson J. High prevalence of left ventricular systolic and diastolic asynchrony in patients with congestive heart failure and normal QRS duration. Heart. 2003;89:54-60.
57. Ghio S, Constantin C, Klersy C, Serio A, Fontana A, Campana C, et al. Interventricular and intraventricular dyssynchrony are common in heart failure patients, regardless of QRS duration. Eur Heart J. 2004;25:571-8.
58. Bader H, Garrigue S, Lafitte S, Reuter S, Jais P, Haissaguerre M, et al. Intra-left ventricular electromechanical asynchrony. A new independent predictor of severe cardiac events in heart failure patients. J Am Coll Cardiol. 2004;43:248-56.
59. Beltrami A, Urbanek K, Kajstura J, Yan S, Finato N, Bussani R, et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med. 2001;344:1750-7.
60. Quaini F, Urbanek K, Beltrami A, Finato N, Beltrami C, Nadal-Ginard B, et al. Chimerism of the transplanted heart. N Engl J Med. 2002;346:5-15.
61. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson S, Li B, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410:701-5.
62. Anversa P, Nadal-Ginard B. Myocyte renewal and ventricular remodelling. Nature. 2002;415:240-3..
63. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA. 2001;98: 10344-9.
64. Hamano K, Nishida M, Hirata K, Mikamo A, Li T, Harada M, et al. Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease: clinical trial and preliminary results. Jpn Circ J. 2001;65:845-7.
65. Strauer B, Brehm M, Zeus T, Kostering M, Hernández A, Sorg R, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002;106:1913-8.
66. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002;106:3009-17.
67. Perin E, Dohmann H, Borojevic R, Silva S, Sousa A, Mesquita C, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003;107:2294-302.
68. Stamm C, Westphal B, Kleine HD, Petzsch M, Kittner C, Klinge H, et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet. 2003;361:45-6.
69. Tse H, Kwong Y, Chan J, Lo G, Ho C, Lau C. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet. 2003;361:47-9.
70. Fuchs S, Satler L, Kornowski R, Okubagzi P, Weisz G, Baffour R, et al. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: a feasibility study. J Am Coll Cardiol. 2003;41:1721-4.
71. Menasche P, Hagege A, Vilquin J, Desnos M, Abergel E, Pouzet B, et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol. 2003;41:1078-83.
72. Herreros J, Prosper F, Pérez A, Gavira J, García-Velloso M, Barba J, et al. Autologous intramyocardial injection of cultured skeletal muscle-derived stem cells in patients with non-acute myocardial infarction. Eur Heart J. 2003;24:2012-20.
73. Avilés F, San Román J, García Frade J, Valdés M, Sánchez A, De la Fuente L, et al. Regeneración miocárdica mediante la implantación intracoronaria de células madre en el infarto agudo de miocardio. Rev Esp Cardiol. 2004;57:201-8.
74. Wollert K, Meyer G, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364:141-8.
75. Kuethe F, Figulla H, Voth M, Richartz B, Opfermann T, Sayer H, et al. Mobilization of stem cells by granulocyte colony-stimulating factor for the regeneration of myocardial tissue after myocardial infarction. Dtsch Med Wochenschr. 2004;129:424-8.
76. Kang H, Kim H, Zhang S, Park K, Cho H, Koo B, et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet. 2004;363:751-6.
77. Balsam L, Wagers A, Christensen J, Kofidis T, Weissman I, Robbins R. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature. 2004;428:668-73.
78. Murry C, Soonpaa M, Reinecke H, Nakajima H, Nakajima H, Rubart M, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature. 2004; 428:664-8.
79. Hocht-Zeisberg E, Kahnert H, Guan K, Wulf G, Hemmerlein B, Schlott T, et al. Cellular repopulation of myocardial infarction in patients with sex-mismatched heart transplantation. Eur Heart J. 2004;25:749-58.